---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093942"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:54:25.696668+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics Q2 net loss $12.4M; RIVER trial ~80% enrolled, topline Q4 2024

## Summary
- Q2 2024 net loss of $12.4M vs $7.1M in Q2 2023; R&D expenses $10.0M, up from $5.8M.
- Cash and equivalents $69.5M; cash runway expected into 2026.
- Phase 2a RIVER trial (RCC) ~80% enrolled; topline data expected Q4 2024.
- Phase 2b CORAL trial (IPF cough) sample size re-estimation expected Q4 2024; topline H1 2025.
- Appointed Margaret Garin, MD, MSCR as VP of Clinical Development.

## SEC filing metadata
- accession: 0000950170-24-093942
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000095017024093942/0000950170-24-093942-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000095017024093942/trvi-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093942
- JSON: https://secwatch.observer/filing/0000950170-24-093942.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093942.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.